Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an update.
Ascletis Pharma Inc. has completed a pre-New Drug Application consultation with the China National Medical Products Administration for its drug denifanstat (ASC40), aimed at treating moderate-to-severe acne vulgaris. The drug has shown significant efficacy and a favorable safety profile in Phase III trials, with no severe adverse events reported. Ascletis plans to submit an NDA soon, which could enhance its market position in dermatological treatments in Greater China.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company primarily targets therapeutic areas such as viral diseases, cancer, and dermatological conditions, with a market focus on Greater China.
Average Trading Volume: 9,654,992
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.51B
For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.